

**PHARMACY AND THERAPEUTICS (P&T) COMMITTEE**  
**May 13, 2020**

The meeting of the Pharmacy and Therapeutics (P&T) Committee of the North Carolina State Health Plan for Teachers and State Employees (The Plan) was called to order at 6:30 P.M. (EST) on Wednesday, May 13, 2020, via webinar, accessible to the public through the Plan's website. Quorum was present.

**MEMBERS PRESENT:**

Sundhar Ramalingam, MD, Oncologist, Duke Cancer Center  
Peter Robie, MD, General Internist, Wake Forest Baptist Community Physicians  
Tony Gurley, RPh, JD, Owner/Pharmacy Manager, Glenwood South Pharmacy + Market  
John J. Engemann, MD, Infectious Disease Specialist, Raleigh Infectious Disease Associates, PA  
Joseph Shanahan, MD, Owner, Shanahan Rheumatology & Immunotherapy  
David Konanc, MD, Neurologist, Raleigh Neurology Associates  
John Anderson, MD, MPH, Chief Medical Officer, Duke Primary Care  
Jennifer Burch, PharmD, Owner, Central Compounding Center  
Matthew K. Flynn, MD, Founder, Family Dermatology

**MEMBERS ABSENT:**

None

**PLAN & VENDOR STAFF:**

Kautook Vyas, PharmD, Senior Pharmacy Consultant, Chairperson  
Caroline Smart, Sr. Director, Plan Integration, State Health Plan  
Dee Jones, Executive Director, State Health Plan  
Natasha Davis, Sr. Pharmacy Benefits Program Manager, State Health Plan  
Renee Jarnigan, RPh, Clinical Advisor, CVS Health  
Stephanie R. Morrison, PharmD, BCPS, Clinical Advisor, CVS Health

*Welcome:*

The Chairperson welcomed the Committee members and guests to the webinar and performed roll call.

*Conflict of Interest*

In compliance with the requirements of Chapter 138A-15(e) of the State Government Ethics Act the Chairperson read the NCSHP's Ethics Awareness & Conflict of Interest Reminder to the P&T Committee members and requested that members who have either an actual or perceived conflict of interest identify the conflict and refrain from discussion and voting in those matters as appropriate. No conflicts of interest were noted.

*Formulary Updates:*

The Chairperson introduced CVS Caremark's Clinical Advisors Heather Renee Jarnigan, RPh, & Stephanie Morrison, PharmD, BCPS whom would be presenting CVS Caremark's Quarterly Formulary Updates, effective July 1, 2020. This included drug removals and additions to the formulary as well as tier changes and utilization management policies.

Ms. Jarnigan began by explaining that the Plan has a formulary exclusion exception process that is available to support Plan members who, per their provider, have a medical necessity to remain on an excluded drug. Ms. Jarnigan then reviewed the following products that will be excluded from the formulary starting on the effective date: ZONTIVITY TAB; DEXCHLORPHENIRAMINE SYRUP 2MG/5ML; RYCLORA SYRUP 2MG/5ML; PRODIGEN CAP; CHLORDIAZEPOXIDE/CLIDINIUM CAP 5-2.5MG LANTHANUM CHEWABLE TABS; KETOPROFEN CAP 200MG ER; MIGERGOT SUPPOSITORY; CYCLOBENZAPRINE TAB 7.5MG; FEXMID TAB 7.5MG; FOLVITE-D TAB; KETOCONAZOLE FOAM 2%; KETODAN; ACYCLOVIR CREAM; ATOPADERM CREAM; VEREGEN; DIHYDROERGOT SPR 4MG/ML; REPATHA; CLINDAMYCIN GEL 1% (NDC 68682046275 - Oceanside Pharmaceuticals Only); FLURANDRENOLIDE LOT 0.05% (NDC 24470092112 - Cintex Pharmaceuticals Only); DOXYCYCLINE MONOHYDRATE 75 MG and 150 MG; OKEBO; MONODOXYNE NL; DOXYCYCLINE HYCLATE TAB 50MG (NDC 72143021160 - JG Pharma Only); DOXYCYCLINE HYCLATE 75MG and 150MG TABS; DOXYCYCLINE HYCLATE Delayed-Release TAB 200MG DR; MINOCYCLINE Extended-Release TAB; COREMINO; FLUCYTOSINE CAP 500MG; POSACONAZOLE Delayed-Rel TAB; FLUOXETINE TAB 60MG; BUPROPION TAB 450MG XL  
KETOPROFEN CAP 25MG; ERGOT/CAFFEN TAB 1-100MG; SUMATRIPTAN-NAPROXEN SODIUM TAB; TREXIMET; CHLORZOXAZONE TAB 375MG and 750MG; LORZONE; CYCLOBENZAPRINE ER BIMATOPROST 0.03% OPHTH; HYDROCORTISONE BUTYRATE CREAM 0.1%; TRIAMCINOLONE ACETONIDE AEROSOL SPRAY; CONSENSI; NORGESIC FORTE; ORPHENGESIC FORTE; ORPHENADRINE/ASPIRIN/CAFFEINE TAB. All products being removed have therapeutic alternatives or generic equivalents that are covered as preferred products on the Plan's custom formulary.

Ms. Jarnigan identified all the branded products that will be moving to a non-preferred status, or up tiered/down tiered. They included: LYRICA CAPSULES and SOLUTION; LOVENOX INJ; BELVIQ; BELVIQ XR; SENSIPAR; ULORIC; ISORDIL TITRADOSE; APRISO; NUVARING; DAYPRO; MOBIC ULTRAM; ESGIC; ZANAFLEX TAB 4MG; MIRCETTE TAB 28.

Ms. Jarnigan along with Dr. Morrison identified all the medications that were being removed from CVS's New-to-Market block and would be available as covered products effective July 1, 2020, along with utilization management policies that went along with the new products and new molecular entities. The new medications being added to the formulary are as follows: OSPHENA; LO LOESTRIN; SYMTUZA; PRALUENT; TAKHZYRO; VERZENIO; STELARA VIA 5MG/ML (IV); REYVOW; UBRELVY; BAQSIMI; ONEXTON GEL 1.2-3.75; ASPARLAS INJ; TRIKAFTA; PRETOMANID; RECARBRIO; ADAKVEO; FETROJA; VUMERITY; NURTEC ODT; REYVOW; UBRELVY; YULPERI; KOSELUGO; TEGSEDI; and BRYHALI LOT 0.01%. There was no other opposition from the Committee members, so the other product additions were approved as presented.

The Committee was also presented with new specialty guideline management additions and line extensions. Feedback was provided from the committee that the meeting be structured in a way that may foster more open dialog. This will be incorporated in the upcoming meeting.

*Adjourn*

Mr. Vyas addressed the Committee by thanking them for their service and informed them that the next meeting would be held on August 12, 2020 at 6:30 P.M. via webinar. The meeting was adjourned at approximately 8:03 P.M. (EST).

*Kautook Vyas*

---

Kautook Vyas, Chair